JNJ vs ABBV

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus 6. 0% for Johnson & Johnson (JNJ). Johnson & Johnson (JNJ) offers the better valuation at 24. 4x trailing P/E (23. 4x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Johnson & Johnson (JNJ) is the cheapest at 24.

4x versus AbbVie Inc. at 111. 9x. On forward P/E, AbbVie Inc. is actually cheaper at 18. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +175. 8%, compared to +78. 0% for Johnson & Johnson (JNJ). Over 10 years, the gap is even starker: ABBV returned +385. 9% versus JNJ's +162. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at -0.

16β versus AbbVie Inc. 's -0. 09β — meaning ABBV is approximately -43% more volatile than JNJ relative to the S&P 500.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus 6. 0% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: Johnson & Johnson grew EPS 90. 5% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, JNJ leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 28.

5% net margin versus 6. 9% for AbbVie Inc. — meaning it keeps 28. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus 27. 2% for JNJ. At the gross margin level — before operating expenses — JNJ leads at 72. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 18. 9x forward P/E versus 23. 4x for Johnson & Johnson — 4. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 8. 2% to $287. 08.

All stocks in this comparison pay dividends.

AbbVie Inc. (ABBV) offers the highest yield at 2. 5%, versus 1. 9% for Johnson & Johnson (JNJ).

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 09), 2. 5% yield, +385. 9% 10Y return). Both have compounded well over 10 years (ABBV: +385. 9%, JNJ: +162. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.